The hazard of each MACE component (ie, myocardial infarction, ischemic or hemorrhagic stroke, cardiac death) and MAKE component (ie, stage 5 CKD or ESKD) was consistently lower with tirzepatide compared with GLP-1 RAs, with AHRs ranging from 0.78 (95% CI, 0.67-0.91) to 0.91 (95% CI, 0.56-1.45) for MACE components and from 0.45 (95% CI, 0.25-0.82) to 0.49 (95% CI, 0.35-0.67) for MAKE components (eTable 5 in Supplement 1). This evidence concerns the gene GLP1R and hemorrhagic stroke.